SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
KSKizzmekia S. CorbettDKDarin K. EdwardsSRSarah R. LeistOMOlubukola M. AbionaSBSeyhan Boyoglu-Barnum
National Institutes of Health · National Institute of Allergy and Infectious Diseases · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,641
total citations
- FWCI
- 30.58
- Percentile
- 100%
- References
- 48
Citations per year
Authors
62- KSKizzmekia S. CorbettCorresponding
National Institutes of Health, National Institute of Allergy and Infectious Diseases
- DKDarin K. Edwards
Moderna Therapeutics (United States)
- SRSarah R. Leist
University of North Carolina at Chapel Hill
- OMOlubukola M. Abiona
National Institutes of Health, National Institute of Allergy and Infectious Diseases
- SBSeyhan Boyoglu-Barnum
National Institutes of Health, National Institute of Allergy and Infectious Diseases
Topics & keywords
Topics
Keywords
- Preparedness
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Coronavirus disease 2019 (COVID-19)
- Virology
- Pathogen
- 2019-20 coronavirus outbreak
- Biology
- Computational biology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of Health and Human ServicesAwards: HHSN261200800001E, 75A50120C00034, HHSN272201700036I
- LLeidosAward: HHSN261200800001E
- NINational Institutes of HealthAwards: AI149644, AI127521, HHSN261200800001E, AI100625, 5494549, R01-AI127521, HHSN272201700036I, 75N93019F00132, T32-AI007151
- BABiomedical Advanced Research and Development AuthorityAwards: 75A50120C00034, contract 75A50120C00034
- NONIH Office of the DirectorAward: HHSN261200800001E
- NINational Institute of Allergy and Infectious DiseasesAwards: 75N93019F00132, AI100625, AI149644, R01-AI127521, HHSN261200800001E, HHSN272201700036I, AI127521, T32-AI007151
- NDNHLBI Division of Intramural Research